Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the …
Biotechnology
US, Cambridge [HQ]
Financials
Earnings Call Transcripts
Earnings Call · Transcripts · SpeakersThis analysis tool shows transcript versions of the official earnings calls hosted by Intellia Therapeutics, Inc.
Could not find a transcript
Peers Transcripts
Peers AnalysisUpcoming Transcript Tools
- Full Text Search - Across All Transcripts
- Detail Speaker Profiles
- Non-US Transcripts